Antisense oligonucleotides in cutaneous therapy

Pharmacology and Therapeutics

Volumn 90, Issue 1, 2001, Pages 89-104

  Wraight, Christopher J ^a   White, Paul J ^a,b  

^a MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Antisense oligonucleotides; Cutaneous delivery; Dermatology; DNA; Skin disease

Indexed keywords

ALICAFORSEN; ANTISENSE OLIGONUCLEOTIDE; C5 PROPYNYLDEOXYURIDYLDEOXYCYTIDYLPHOSPHOROTHIOIC ACID DERIVATIVE; CISPLATIN; FOMIVIRSEN; PHOSPHOROTHIOIC ACID DERIVATIVE; PSORALEN; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG;

ANEMIA; CHEMICAL STRUCTURE; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG INDUCED DISEASE; DRUG MECHANISM; ELECTROPORATION; GENE GUN; GENE THERAPY; HUMAN; IONTOPHORESIS; KAPOSI SARCOMA; KERATODERMA; LYMPHOID HYPERPLASIA; MELANOMA; MERKEL CELL TUMOR; NONHUMAN; PIGMENT DISORDER; PRIORITY JOURNAL; PROTEIN TARGETING; PSORIASIS; REVIEW; SKIN CANCER; THROMBOCYTOPENIA; VIRAL SKIN DISEASE; WOUND HEALING;

ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; DERMATOLOGIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; GENE THERAPY; HUMANS; MOLECULAR STRUCTURE; OLIGONUCLEOTIDES, ANTISENSE; RNA, MESSENGER; SKIN DISEASES; SKIN NEOPLASMS; THIONUCLEOTIDES;

EID: 0034945428     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(01)00133-4     Document Type: Review

References (119)

1. Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration
2. Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA
3. Phosphorothioate oligonucleotides inhibit the replication of lentiviruses and type D retroviruses, but not that of type C retroviruses
4. Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region
5. Therapeutic approaches to papillomavirus infections
6. Role of endogenous endonucleases and tissue site in transfection and CpG-mediated immune activation after naked DNA injection
7. Binding of phosphorothioate oligodeoxynucleotides to basic fibroblast growth factor, recombinant soluble CD4, laminin and fibronectin is P-chirality independent
8. Inhibition of endothelial cell adhesion molecule expression with antisense oligonucleotides
9. Electroporation enhances c-myc antisense oligodeoxynucleotide efficacy
10. An assessment of the antisense properties of RNase H-competent and steric-blocking oligomers
11. Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms
12. Control of scarring in adult wounds using antisense transforming growth factor-beta 1 oligodeoxynucleotides
13. c-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice
14. Effect of antisense oligonucleotides on cytokine release from human keratinocytes in an in vitro model of skin
15. Molecular mechanisms of antisense drugs: RNase H
16. Vitravene - Another piece in the mosaic
17. Pharmacokinetic properties of several novel oligonucleotide analogs in mice
18. Inhibition of protein kinase C-alpha expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters
19. Fomivirsen - A phosphorothioate oligonucleotide for the treatment of CMV retinitis
20. Isis and antisense face crucial test without Novartis
21. On the quality control of antisense oligonucleotides
22. Intracellular disposition and metabolism of fluorescently-labeled unmodified and modified oligonucleotides microinjected into mammalian cells
23. Potent and selective gene inhibition using antisense oligodeoxynucleotides
24. Effects of oligonucleotide length, mismatches and mRNA levels on C-5 propyne-modified antisense potency
25. Cellular penetration and antisense activity by a phenoxazine-substituted heptanucleotide
26. A cytosine analog that confers enhanced potency to antisense oligonucleotides
27. Cloning, subcellular localization and functional expression of human RNase HII
28. Effect of phosphorothioate homo-oligodeoxynucleotides on herpes simplex virus type 2-induced DNA polymerase
29. Inhibition of herpes simplex virus type 2 growth by phosphorothioate oligodeoxynucleotides
30. Mechanisms of inhibition of herpes simplex virus type 2 growth by 28-mer phosphorothioate oligodeoxycytidine
31. Increased oligonucleotide permeability in keratinocytes of artificial skin correlates with differentiation and altered membrane function
32. Differential regulation of c-fos, fosB, c-jun, junB, bcl-2 and bax expression in rat skin following single or chronic ultraviolet irradiation and in vivo modulation by antisense oligodeoxynucleotide superfusion
33. Inhibition of c-Fos expression in the UV-irradiated epidermis by topical application of antisense oligodeoxynucleotides suppresses activation of proliferating cell nuclear antigen
34. Progress in developments of triplex-based strategies
35. In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration
36. Kinesin participates in melanosomal movement along melanocyte dendrites
37. Ribonuclease H. An enzyme degrading the RNA moiety of DNA-RNA hybrids
38. Comparison of the toxicity profiles of ISIS 1082 and ISIS 2105, phosphorothioate oligonucleotides, following subacute intradermal administration in Sprague-Dawley rats
39. Inhibition of interferon-gamma-induced intercellular adhesion molecule-1 expression on human keratinocytes by phosphorothioate antisense oligodeoxynucleotides is the consequence of antisense-specific and antisense-non-specific effects
40. The insulin-like growth factor 1 receptor is expressed by epithelial cells with proliferative potential in human epidermis and skin appendages: Correlation of increased expression with epidermal hyperplasia
41. Inhibition of atypical PKC blocks ultraviolet-induced AP-1 activation by specifically inhibiting ERKs activation
42. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice
43. Pathogenesis of psoriasis
44. Multiple mechanisms may contribute to the cellular anti-adhesive effects of phosphorothioate oligodeoxynucleotides
45. Inhibition of wound-induced expression of transforming growth factor-beta 1 mRNA by its antisense oligonucleotides
46. Synergistic effects of epidermal growth factor (EGF) and insulin-like growth factor I/somatomedin C (IGF-I) on keratinocyte proliferation may be mediated by IGF-I transmodulation of the EGF receptor
47. The insulin-like growth factor I receptor is overexpressed in psoriatic epidermis, but is differentially regulated from the epidermal growth factor receptor
48. Phosphorothioate oligodeoxynucleotides: Antisense or anti-protein?
49. Role of growth factors, cytokines, and their receptors in the pathogenesis of psoriasis
50. Characterisation of membrane oligonucleotide-binding proteins and oligonucleotide uptake in keratinocytes
51. Definition by specific antisense oligonucleotides of a role for protein kinase C alpha in expression of differentiation markers in normal and neoplastic mouse epidermal keratinocytes
52. Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin
53. Antisense oligonucleotides targeting human protein kinase C-alpha inhibit phorbol ester-induced reduction of bradykinin-evoked calcium mobilization in A549 cells
54. Description of the intrafollicular delivery of large molecular weight molecules to follicles of human scalp skin in vitro
55. Inhibition of collagenase type I expression by psoralen antisense oligonucleotides in dermal fibroblasts
56. Intracellular mRNA cleavage induced through activation of RNase P by nuclease-resistant external guide sequences
57. Vascular endothelial adhesion molecules and tissue inflammation
58. Phosphorothioate oligodeoxyribonucleotides dissociate from cationic lipids before entering the nucleus
59. First "antisense" drug will treat CMV retinitis
60. Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma
61. Prediction of antisense oligonucleotide efficacy by in vitro methods
62. Adhesion molecules in autoimmune disease
63. Intercellular adhesion molecule-1 suppression in skin by topical delivery of anti-sense oligonucleotides
64. Oligonucleotide therapy of allergic asthma
65. A new approach to chemotherapy based on molecular biology and nucleic acid chemistry: Matagen (masking tape for gene expression)
66. Selecting effective antisense reagents on combinatorial oligonucleotide arrays
67. The use of single-stranded DNA and RNase H to promote quantitative 'hybrid arrest of translation' of mRNA/DNA hybrids in reticulocyte lysate cell-free translations
68. Degradation of deoxyribonucleic acid by guinea pig epidermal extracts
69. Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression
70. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase
71. Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo
72. Human cytomegalovirus mutant with sequence-dependent resistance to the phosphorothioate oligonucleotide fomivirsen (ISIS 2922)
73. Bcl-2 expression in epidermal keratinocytic diseases
74. Cationic lipid is not required for uptake and selective inhibitory activity of ICAM-1 phosphorothioate antisense oligonucleotides in keratinocytes
75. DNA antisense therapy for asthma in an animal model
76. Iontophoretic delivery of oligonucleotides across full thickness hairless mouse skin
77. Sequence-independent induction of Sp1 transcription factor activity by phosphorothioate oligodeoxynucleotides
78. Fomivirsen
79. Fomiversen sodium approved to treat CMV retinitis
80. Localization of a FITC-labeled phosphorothioate oligodeoxynucleotide in the skin after topical delivery by iontophoresis and electroporation
81. Effect of insulin-like growth factor-I/somatomedin C on thymidine incorporation in cultured psoriatic keratinocytes after growth arrest in growth factor-free medium
82. Increased synergistic effect of EGF and IGF-I on DNA synthesis of cultured psoriatic keratinocytes
83. Crohn's trial shows the pros of antisense
84. Cell-surface perturbations of the epidermal growth factor and vascular endothelial growth factor receptors by phosphorothioate oligodeoxynucleotides
85. In vivo toxicological effects of rel A antisense phosphorothioates in CD-1 mice
86. Bcl-2 antisense oligonucleotides (G3139) inhibit Merkel cell carcinoma growth in SCID mice
87. Papillomaviruses as targets for cancer gene therapy
88. Antisense oligonucleotides inhibit vascular endothelial growth factor/vascular permeability factor expression in normal human epidermal keratinocytes
89. Inhibition of proliferation of human melanocytes by a KIT antisense oligodeoxynucleotide: Implications for human piebaldism and mouse dominant white spotting (W)
90. Does antisense exist?
91. Phosphorothioate antisense oligodeoxynucleotides: Questions of specificity
92. How to design an antisense oligodeoxynucleotide experiment: A consensus approach
93. Is irrelevant cleavage the price of antisense efficacy?
94. Phosphorothioate oligodeoxynucleotides are potent sequence nonspecific inhibitors of de novo infection by HIV
95. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide
96. T-lymphocyte clones initiated from lesional psoriatic skin release growth factors that induce keratinocyte proliferation
97. In vivo cytokine gene transfer by gene gun reduces tumor growth in mice
98. Inhibition of Bcl-xL expression sensitizes normal human keratinocytes and epithelial cells to apoptotic stimuli
99. Cellular pharmacology and protein binding of phosphoromonothioate and phosphorodithioate oligodeoxynucleotides: A comparative study
100. DNA immunization targeting the skin: Molecular control of adaptive immunity
101. Intercellular adhesion molecule-1
102. Iontophoretic delivery of oligonucleotide derivatives into mouse tumor
103. Gene inhibition using antisense oligodeoxynucleotides
104. Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines
105. Potent and selective inhibition of gene expression by an antisense heptanucleotide
106. Role of RNase H in hybrid-arrested translation by antisense oligonucleotides
107. The expression of C-myb in human metastatic melanoma cell lines and specimens
108. Live confocal microscopy of oligonucleotide uptake by keratinocytes in human skin grafts on nude mice
109. Oligonucleotide uptake in cultured keratinocytes: Influence of confluence, cationic liposomes, and keratinocyte cell type
110. Antisense inhibition of IGF receptor expression in HaCaT keratinocytes: A model for antisense strategies in keratinocytes
111. Flow cytometric and microscopic characterization of the uptake and distribution of phosphorothioate oligonucleotides in human keratinocytes
112. Expression of insulin-like growth factor binding protein-3 (IGFBP-3) in the psoriatic lesion
113. Reversal of epidermal hyperproliferation in psoriasis by insulin-like growth factor I receptor antisense oligonucleotides
114. Dermal injection of immunocytes induces psoriasis
115. Altered insulin-like growth factor-II (IGF-II) level and IGF-binding protein-3 (IGFBP-3) protease activity in interstitial fluid taken from the skin lesion of psoriasis
116. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease
117. Oligodeoxynucleotides interact with recombinant CD4 at multiple sites
118. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide
119. In vivo stability, disposition and metabolism of a "hybrid" oligonucleotide phosphorothioate in rats